Abstract:Pinyi Zhang, 1 Jianlong Bu, 2 Xiaohong Wu, 1 Lin Deng, 1 Meng Chi, 1 Chao Ma, 3 Xiaoding Shi, 1 Guonian Wang 3 1 Department of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China; 2 Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China; 3 Department of Anesthesiology, The Fourth Hospital of Harbin Medical University, Harbin, People's Republic of China Correspondence: Guonian Wang Department of Anesthesiology, The Fourth Hospital of Harbin Medical University, Nangang District, Harbin 150081, People's Republic of China Tel +86 15804616023 Email wangguonian609cn@aliyun.com Background: Sustained morphine treatment for cancer pain has been limited due to analgesic tolerance. Opioid receptor internalization and desensitization mediated by downregulation of mu-opioid receptor (MOR) expression have been confirmed as one of the mechanisms of chronic morphine tolerance. In addition to the opiate system, the α 2-adrenergic system is involved in the development of morphine tolerance. Several studies reported that co-administration of α 2-adrenoceptor agonist dexmedetomidine inhibits morphine tolerance in normal or neuropathic pain animals. However, the effect of dexmedetomidine on morphine tolerance has not been studied in cancer pain. Therefore, we investigated the effect of intrathecal injection of dexmedetomidine on the development of morphine tolerance in cancer pain and on the expression of MOR in the spinal cord of morphine-tolerant cancer pain rats. Methods: The model was established using a rat's right hind paw injection of Walker 256 cancer cells. Subcutaneous morphine (10mg/kg) was administrated twice daily for 7 days; meanwhile, the rats received intrathecal α 2-adrenoceptor agonist dexmedetomidine (10μ/kg) or antagonist MK-467 (0.25mg/kg) in test groups. Rats receiving drug vehicle served as the control group. Antinociception was detected by von Frey filaments and hot-plate tests. The expression of MOR in the spinal cord was examined through real-time reverse transcription polymerase chain reaction and Western blotting. The data were analyzed via analysis of variance followed by Student t -test with Bonferroni correction. Results: Seven-day chronic morphine administration elicited notable analgesic tolerance in the rats with cancer pain. Co-administration of α 2-adrenoceptor agonist dexmedetomidine enhanced morphine analgesia and attenuated morphine tolerance, which could be blocked by α 2-adrenoceptor antagonist MK-467. Furthermore, pre-treatment of dexmedetomidine significantly upregulated MOR protein expression without a notable change in MOR mRNA expression in the spinal cord. Conclusion: Our findings suggest that intrathecal injection of dexmedetomidine enhanced morphine analgesia and attenuated morphine tolerance in cancer pain, potentially by upregulating MOR expression in the spinal cord. The α 2-adrenoceptor agonist may provide a more versatile analgesia option for morphine treatment for cancer pain. Keywords: μ-opioid receptor, MOR, α 2-adrenoceptor, α 2-AR, dexmedetomidine, DEX, morphine tolerance, cancer pain

Antagonism of Morphine-Induced Antinociception by Tetrandrine is Dependent on Serotonergic Mechanisms.

Experimental Colitis Enhances the Rate of Antinociceptive Tolerance to Morphine Via Peripheral Opioid Receptors

Methadone and heroin antinociception: predominant delta-opioid-receptor responses in methadone-tolerant mice

Disruption of Cdk5-Associated Phosphorylation of Residue Threonine-161 of the Delta-Opioid Receptor: Impaired Receptor Function and Attenuated Morphine Antinociceptive Tolerance

Effects of 5-hydroxytryptophan on morphine-induced sensitization in mice

Reduction of Prefrontal Purinergic Signaling is Necessary for the Analgesic Effect of Morphine

The 5-HT3B subunit affects high-potency inhibition of 5-HT3 receptors by morphine

The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence

The Effects of 1-THP on Morphine-Induced Discrimionation

Involvement of 5-hydroxytryptamine1A receptors in the descending anti-nociceptive pathway from periaqueductal gray to the spinal dorsal horn in intact rats, rats with nerve injury and rats with inflammation

Teneligliptin Co-Infusion Alleviates Morphine Tolerance by Inhibition of Spinal Microglial Cell Activation in Streptozotocin-Induced Diabetic Rats

Morphine Withdrawal-Induced Hyperalgesia in Models of Acute and Extended Withdrawal Is Attenuated by l-Tetrahydropalmatine

Upregulation of μ-Opioid Receptor in the Rat Spinal Cord Contributes to the α2-Adrenoceptor Agonist Dexmedetomidine-Induced Attenuation of Chronic Morphine Tolerance in Cancer Pain

Toll-like Receptor 2-Melatonin Feedback Loop Regulates the Activation of Spinal NLRP3 Inflammasome in Morphine-Tolerant Rats

Tumor necrosis factor-α-induced protein 8-like 2 alleviates morphine antinociceptive tolerance through reduction of ROS-mediated apoptosis and MAPK/NF-κB signaling pathways

A New Buprenorphine Analogy, Thenorphine,inhibits Morphine-Induced Behavioral Sensitization in Mice

Effects of 5-HT1A Receptor Antagonist and 5-HT2A Receptor Agonist on Morphine Withdrawal

Influence of l-tetrahydropalmatine on morphine-induced conditioned place preference

Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine

Tetrandrine attenuates SNI-induced mechanical allodynia by inhibiting spinal CKLF1

Dysregulation of Vesicular Glutamate Transporter VGluT2 Via BDNF/TrkB Pathway Contributes to Morphine Tolerance in Mice